Intervention not reported
The intervention showed no clear difference in minor adverse events (low certainty).
- RR 1.51 [0.98, 2.33]4 studies · 254 participantsLow
The intervention showed no clear difference in minor adverse events (low certainty).
Antimicrobial showed no clear difference in minor adverse events compared with placebo or no antibiotics (low certainty).
Desmopressin showed no clear difference in minor adverse events compared with placebo (low certainty).
It is very uncertain whether desmopressin changes minor adverse events compared with alpha‐blocker (very low certainty).
It is very uncertain whether desmopressin plus alpha‐blocker changes minor adverse events compared with alpha‐blocker (very low certainty).
Desmopressin plus alpha‐blocker may leads to lower minor adverse events compared with alpha‐blocker plus anticholinergic (low certainty).
It is very uncertain whether macrolides changes minor adverse events compared with any other antibiotic (very low certainty).
It is very uncertain whether macrolide (erythromycin) changes minor adverse events compared with any other macrolide (very low certainty).
Oral retinoids: alitretinoin 10 mg showed no clear difference in primary: all adverse events compared with placebo (moderate certainty).
Topical triamcinolone acetonide led to lower adverse events (split-mouth) compared with cryotherapy; GRADE not reported.
Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).
Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).
Oral methotrexate showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in all serious adverse events compared with placebo/open control (high certainty).
Oral contraceptive pill (OCP) may leads to lower adverse events ‐ Minor compared with metformin combined with OCP (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.